-+ 0.00%
-+ 0.00%
-+ 0.00%

NOVO'S SOGROYA® RECEIVES FDA APPROVAL AS THE FIRST AND ONLY ONCE-WEEKLY, LONG-ACTING GROWTH HORMONE FOR CHILDREN WITH TURNER SYNDROME (TS)

Reuters·11/20/2026 16:47:47

Please log in to view news